

Today marks 10 years since the European Medicines Agency (EMA) approved the world’s first monoclonal antibody biosimilar infliximab, for all indications of...


Encouraging objective response rate of 52.4% was seen with ifinatamab deruxtecan in heavily pretreated patients IDeate-01 phase 2 trial currently enrolling patients...


An objective response rate of 29.8% was observed with patritumab deruxtecan in heavily pretreated patients BLA submission in U.S. planned for the...


Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab with or without chemotherapy demonstrated objective response rates of 77% and 50% and disease...


 TAIPEI,Taiwan–(BUSINESS WIRE)–TVBS, the Taiwanese broadcasting network that kicked off operations in 1993, marks its three-decade anniversary with a significant exhibition entitled...


SINGAPORE–(BUSINESS WIRE)–#insurance—AM Best has downgraded the Financial Strength Rating to B++ (Good) from A- (Excellent) and the Long-Term Issuer Credit Rating to...


The Australian-born brand beloved by Gen Z makes its U.S. debut SAN FRANCISCO–(BUSINESS WIRE)–a.k.a. Brands Holding Corp. (NYSE: AKA), a brand accelerator...


Financial LLM is in closed test with financial institution partners on Ant Group’s wealth management and insurance platforms The company will implement...


PARIS–(BUSINESS WIRE)–Zhuyeqing Tea is regarded as the gift of China in the New Silk Road after it was highly praised on 2023...


HONG KONG–(BUSINESS WIRE)–At this year’s INCLUSION · Conference on the Bund, Ant Group Digital Technologies launched a new brand called ZAN which...